Asthma Drug Cuts Need For Steroid Pills While Keeping Attacks In Check

Follow Drugslib on

By Dennis Thompson HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

TUESDAY, June 2, 2026 — A recently approved asthma drug can help those with asthma take fewer steroid drugs while keeping attacks under control, according to clinical trial results.

People taking tezepelumab (Tezspire) were nearly three times more likely to achieve greater reductions in daily steroid use while maintaining asthma control, compared to those on a placebo, researchers reported recently in The Lancet Respiratory Medicine.

“Long-term oral corticosteroid use can have devastating consequences for patients, including diabetes, osteoporosis, cardiovascular disease and significant impacts on quality of life,” said lead researcher Dr. Michael Wechsler, director of the Cohen Family Asthma Institute at National Jewish Health in Denver.

The U.S. Food & Drug Administration (FDA) approved tezepelumab in 2021 for maintenance treatment of severe asthma, according to Drugs.com. Individuals with asthma self-inject the drug once a month.

Tezepelumab works by blocking thymic stromal lymphopoietin (TSLP), an inflammation-triggering chemical known as a cytokine. By blocking TSLP, the drug can ward off asthma attacks prompted by multiple different triggers.

For the new study, researchers recruited 122 people taking steroids for their asthma and assigned roughly two-thirds at random to take tezepelumab. The rest were provided a placebo.

During a 28-week treatment period, 69% of patients taking tezepelumab were able to cut their steroid pill dose by half or more, compared to 44% of those on placebo.

In addition, 35% of patients on tezepelumab were able to completely stop taking steroids, compared to 21% in the placebo group, the study found.

“These findings are important because they show that patients with severe asthma treated with tezepelumab may be able to substantially reduce their dependence on oral steroids without sacrificing asthma control,” Wechsler said in a news release.

Researchers noted that the study terminated early due to slow recruitment and did not reach its intended goal of 207 patients.

“Nevertheless, (the trial) was conducted to a high quality, with almost three-quarters of randomly assigned participants completing the study, with early study termination being the most common reason for non-completion,” researchers wrote in their paper.

The drug’s makers, AstraZeneca and Amgen, funded the clinical trial.

Sources

  • National Jewish Health, news release, May 28, 2026
  • The Lancet Respiratory Medicine, May 28, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-06-02 23:14

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords